Oct 19 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX)
VRX.TO
* Valeant CEO says generics with no competitors account for
$75 million in revenues quarterly
* Valeant CEO says growth trend emphasizes volume, not
pricing
* Valeant CEO says is in touch with government on
investigations, declines further comment
* Valeant CEO says sees research and development becoming
more of a focus, says with the stock at these prices it will
consider share buybacks
* Valeant CEO defends pricing strategy saying many Wall
Street analyst reports, media reports are wrong
* Valeant CEO says its patient assistance programs are
administered by a reputable third party
Further company coverage: VRX.TO